Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07573228

Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

The purpose of this study is:

* To see if insulin resistance (how sensitive your muscle tissue is to insulin) is associated with lower cardio fitness in people with Type 1 diabetes compared to healthy controls, before and after a High Intensity Interval Training (HIIT) exercise program. * To see if being overweight and having Type 1 diabetes is associated with lower cardio fitness compared to overweight healthy controls, before and after a HIIT exercise program.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study will test the hypothesis that in humans with T1D skeletal muscle microvascular insulin resistance predicts a reduction in Cardiorespiratory Fitness (CRF) and obesity exacerbates microvascular insulin resistance, leading to further CRF decline, which is mechanistically linked to increased muscle microvascular endothelial oxidative stress, impaired muscle mitochondrial function, reduced muscle capillary density and decreased satellite cells.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Male or female ≥21 and ≤50 years old
  • For persons with T1D: Disease duration ≥ 5 years and HbA1c ≤ 8.5% on multiple daily insulin injection or insulin pump
  • Body mass index: ≥19 and ≤27 kg/m2 for control and T1D, ≥30 and ≤40 kg/m2 (27.5 to 37.5 for Asian Americans) for obesity and T1D + obesity. BMI is limited to ≤40 kg/m2 (37.5 for Asian Americans) for easier vascular access and cardiac imaging.
  • Stable use of non-insulin medications for over 6 months other than estrogen/progesterone containing medications which must be discontinued at least 3 months prior to the study (intrauterine devices may be continued due to limited systemic absorption)

Exclusion criteria

  • • Acute or chronic disease other than T1D or obesity
  • History of microvascular or macrovascular diabetes complications
  • History of diabetic ketoacidosis in the past 24 months
  • History of hypoglycemia unawareness
  • Recently active (>20 min of moderate/high intensity exercise, 2 times/week)
  • Subjects who are smokers or who have quit smoking <5 years
  • Subjects with hypertriglyceridemia (>400 mg/dl)
  • Current use of vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha- or beta-blockers, or diuretics).
  • Females taking oral contraceptives in the past 3 months
  • Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy
  • Pregnant (as evidenced by positive pregnancy test) or nursing women
  • Musculoskeletal condition preventing participation in exercise testing or exercise training
  • History of gastroparesis
  • Pulse oximetry <90%

Treatment and study plan

Exercise training

Other

15 weeks of HIIT exercise training

Primary outcomes

  1. Microvascular blood volume in skeletal and cardiac muscle - changes from baseline

    Time frame: Before and after 15 weeks of exercise training

    insulin-mediated changes in skeletal and cardiac muscle as determined by insulin clamp

  2. maximal aerobic exercise capacity

    Time frame: before and after 15 weeks of exercise training

    change in VO2max

Secondary outcomes

  1. insulin-mediated whole body glucose disposal

    Time frame: before and after 15 weeks of exercise training

    insulin-mediated whole body glucose disposal during insulin clamp

  2. Muscle capillary density and satellite cells

    Time frame: before and after 15 weeks of exercise training

    Changes in muscle capillary density and satellite cells

Study contacts

Contact information is provided by the study sponsor or research team.

Lee Hartline, MEd

CONTACT

[email protected]

434-924-5247

Zhenqi Liu, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Registry information

Official study title

Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes (

Acronym: ZQL010

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
May 7, 2026
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.